EUCTR2012-002324-32-IT进行中（未招募）不适用
A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease-Modifying Antirheumatic Drugs - RA - BEGI
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 550
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •are at least 18 years of age • have a diagnosis of adult-onset RA as defined by ACR/EULAR 2010 Criteria for the Classification of RA • have documented history of positive rheumatoid factor and/or cyclic citrullinated peptide (CCP) antibody test • have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints • have a C-reactive protein (or hsCRP) measurement =1.2 times the upper limit of normal (ULN) • have had limited or no treatment with MTX
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •have received conventional DMARDs other than MTX•are currently receiving corticosteroids at doses >10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids•have started treatment with NSAIDs or have been receiving an unstable dosing regimen of NSAIDs•have started a new physiotherapy treatment for RA in the 2 weeks prior to study entry•have ever received any biologic DMARD•have received interferon therapy within 4 weeks prior to study entry•have received any parenteral corticosteroid administered by intramuscular or intravenous inj•have had 3 or more joints injected with intraarticular corticosteroids•have active fibromyalgia that would make it difficult to appropriately assess RA activity•have a diagnosis of any systemic inflammatory condition other than RA•have a diagnosis of Felty’s syndrome•have had any major surgery within 8 weeks of study entry•have experienced any of the following within 12 weeks of study entry:myocardial infarction,unstable ischemic heart disease,stroke, or NYHA Stage IV heart failure•have a history or presence of cardiovascular,respiratory,hepatic, gastrointestinal,endocrine,hematological,neurological,or neuropsychiatric disorders or any other serious and/or unstable illness•are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair•have an eGFR based on the most recent available serum creatinine using the Modification of Diet in Renal Disease method of <40 mL/min/1.73 m2•have a history of chronic liver disease with the most recent available AST or ALT>1.5 times the ULN or the most recent available total bilirubin =1.5 times the ULN•have lymphoproliferative disease;or signs or symptoms suggestive of possible lymphoproliferative disease,including lymphadenopathy or splenomegaly;or active primary or recurrent malignant disease;or have been in remission from clinically significant malignancy for <5 years•have been exposed to a live vaccine within 12 w prior to planned randomization or are expected to need/receive a live vaccine during the course of the study•have a current or recent clinically serious viral,bacterial,fungal,or parasitic infection•have had symptomatic herpes zoster infection within 12 w prior to study entry•have a history of disseminated/complicated herpes zoster•are immunocompromised •have a history of active hepatitis B virus,hepatitis C virus,or human immunodeficiency virus•have screening laboratory test values outside the reference range for the population or investigative site•have screening ECG abnormalities that are clinically significant•have symptomatic herpes simplex at the time of study enrollment•have evidence of active or latent TB as documented by a positive purified protein
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 20.0Level: PTClassification code 10072579Term: Granulomatosis with polyangiitisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1Level: PTClassification code 10050894Term: Anti-neutrophil cytoplasmic antibody positive vasculitisSystem Organ Class: 10021428 - Immune system disordersEUCTR2016-001121-14-SEChemoCentryx, Inc.300
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).EUCTR2016-001121-14-ATChemoCentryx, Inc.300
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).EUCTR2016-001121-14-HUChemoCentryx, Inc.300
进行中（未招募）
不适用
A Phase 3 Study in Moderate to Severe Rheumatoid ArthritisEUCTR2012-002324-32-DEEli Lilly and Company550
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).EUCTR2016-001121-14-IEChemoCentryx, Inc.300